ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients

Phase 4

Completed

Conditions: Restless Legs Syndrome (RLS)

Interventions: Drug: Placebo
Drug: Gabapentin enacarbil

First Posted Date: 2017-02-15

Last Posted Date: 2024-12-12

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 375

Registration Number: NCT03053427

Locations: 🇯🇵
Site JP00013, Shinagawa, Tokyo, Japan
🇯🇵
Site JP00021, Shinjuku, Tokyo, Japan
🇯🇵
Site JP00041, Kawanishi, Hyogo, Japan

and more 43 locations

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: roxadustat
Drug: DA

First Posted Date: 2016-12-12

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 334

Registration Number: NCT02988973

Locations: 🇯🇵
Site JP00010, Toyama, Japan
🇯🇵
Site JP00057, Kitakyusyu, Fukuoka, Japan
🇯🇵
Site JP00009, Kasugai, Aichi, Japan

and more 63 locations

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: roxadustat

First Posted Date: 2016-11-16

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 100

Registration Number: NCT02964936

Locations: 🇯🇵
Site JP00029, Iwate, Japan
🇯🇵
Site JP00032, Oita, Japan
🇯🇵
Site JP00019, Saitama, Japan

and more 35 locations

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Phase 3

Completed

Conditions: Hemodialysis Chronic Kidney Disease Patients With Anemia

Interventions: Drug: Darbepoetin alfa
Drug: roxadustat

First Posted Date: 2016-11-02

Last Posted Date: 2024-10-30

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 303

Registration Number: NCT02952092

Locations: 🇯🇵
Site JP00033, Aichi, Japan
🇯🇵
Site JP00004, Ehime, Japan
🇯🇵
Site JP00041, Ibaraki, Japan

and more 54 locations

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ASP1517
Drug: Lanthanum carbonate hydrate

First Posted Date: 2016-11-02

Last Posted Date: 2017-01-25

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 18

Registration Number: NCT02952040

Locations: 🇯🇵
Site JP00001, Tokyo, Japan

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Flutamide
Other: Androgen deprivation therapy

First Posted Date: 2016-09-29

Last Posted Date: 2024-12-09

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 206

Registration Number: NCT02918968

Locations: 🇯🇵
Site JP00051, Iizuka, Fukuoka, Japan
🇯🇵
Site JP00019, Sagamihara, Kanagawa, Japan
🇯🇵
Site JP00024, Nagoya, Aichi, Japan

and more 44 locations

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: ipragliflozin
Drug: Placebo
Other: Insulin Therapy

First Posted Date: 2016-09-13

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 175

Registration Number: NCT02897219

Locations: 🇯🇵
Site JP00005, Aichi, Japan
🇯🇵
Site JP00022, Fukuoka, Japan
🇯🇵
Site JP00006, Hiroshima, Japan

and more 33 locations

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: ASP1707
Drug: Methotrexate

First Posted Date: 2016-08-31

Last Posted Date: 2024-10-23

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 72

Registration Number: NCT02884635

Locations: 🇯🇵
Site JP00010, Hiroshima, Japan
🇯🇵
Site JP00022, Aichi, Japan
🇯🇵
Site JP00023, Aichi, Japan

and more 24 locations

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Ipragliflozin
Drug: Insulin

First Posted Date: 2016-07-28

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 103

Registration Number: NCT02847091

Locations: 🇯🇵
Site JP00008, Hiroshima, Japan
🇯🇵
Site JP00002, Tochigi, Japan
🇯🇵
Site JP00004, Osaka, Japan

and more 12 locations

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Phase 3

Completed

Conditions: Chronic Constipation

Interventions: Drug: Placebo
Drug: linaclotide

First Posted Date: 2016-06-22

Last Posted Date: 2024-10-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 186

Registration Number: NCT02809105

Locations: 🇯🇵
Site JP00036, Osaka, Japan
🇯🇵
Site JP00011, Tokyo, Japan
🇯🇵
Site JP00013, Tokyo, Japan

and more 36 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy